Compare · ESTA vs EW
ESTA vs EW
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.78B, about 27.8x ESTA ($1.83B).
- ESTA has been more active in the news (9 items in the past 4 weeks vs 5 for EW).
- EW has more recent analyst coverage (25 ratings vs 15 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $1.83B
- $50.78B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 9
- 5
- Recent ratings
- 15
- 25
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ESTA
- Stifel initiated coverage on Establishment Labs with a new price target
- SEC Form 8-K filed by Establishment Labs Holdings Inc.
- Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
- Director Gillin Leslie was granted 262 shares, increasing direct ownership by 1% to 18,856 units (SEC Form 4)
- Director Schutter Edward J was granted 253 shares, increasing direct ownership by 0.14% to 178,205 units (SEC Form 4)
- Director Lewin Nicholas Sheridan was granted 389 shares, increasing direct ownership by 0.04% to 1,080,349 units (SEC Form 4)
- Director Slotkin Bryan was granted 253 shares, increasing direct ownership by 0.77% to 33,052 units (SEC Form 4)
- Director Custin Ann was granted 301 shares, increasing direct ownership by 1% to 24,626 units (SEC Form 4)
- Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
- Chief Executive Officer Caldini Filippo covered exercise/tax liability with 682 shares, decreasing direct ownership by 1% to 48,829 units (SEC Form 4) (tax liability)
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision